In patients with DM ( n = @ ) , vorapaxar significantly reduced the primary end point ( @ % versus @ % ; hazard ratio , @ -LSB- @ % confidence interval , @-@ @ -RSB- ; P = @ ) with a number needed to treat to avoid @ major cardiovascular event of @ .